Sandra Hervas-Stubbs
Overview
Explore the profile of Sandra Hervas-Stubbs including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
99
Citations
4056
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Martin-Otal C, Sanchez-Moreno I, Gomez-Moron A, Castro C, Casares N, Navarro F, et al.
J Immunother Cancer
. 2025 Feb;
13(2).
PMID: 39988346
Background: Phosphatidylserine (PS) exposed on apoptotic cells promotes immune clearance of dead cells without inducing inflammation. Conversely, PS exposure on live tumor cells promotes an immunosuppressive tumor microenvironment that hinders...
2.
Covo-Vergara A, Salaberry L, Silva-Pilipich N, Hervas-Stubbs S, Smerdou C
Mol Ther Nucleic Acids
. 2024 Dec;
35(4):102395.
PMID: 39669702
No abstract available.
3.
Vercher E, Covo-Vergara A, Conde E, Hernandez-Rueda M, Elizalde E, Mancheno U, et al.
Hepatology
. 2024 Nov;
PMID: 39601444
Background And Aims: Glypican-3 (GPC3) is a promising target for T-cell therapy in HCC. While chimeric antigen receptor (CAR) T cells targeting GPC3 have demonstrated therapeutic efficacy, their effectiveness is...
4.
Cordoba K, Jerico D, Jiang L, Collantes M, Alegre M, Garcia-Ruiz L, et al.
Gut
. 2024 Oct;
74(2):270-283.
PMID: 39366725
Objective: Acute intermittent porphyria (AIP) is a rare metabolic disorder caused by haploinsufficiency of hepatic porphobilinogen deaminase (PBGD), the third enzyme of the heme biosynthesis. Individuals with AIP experience neurovisceral...
5.
Sanchez-Moreno I, Lasarte-Cia A, Martin-Otal C, Casares N, Navarro F, Gorraiz M, et al.
J Immunother Cancer
. 2024 Jul;
12(7).
PMID: 38955421
Background: Adoptive cell therapy using genetically modified T cells to express chimeric antigen receptors (CAR-T) has shown encouraging results, particularly in certain blood cancers. Nevertheless, over 40% of B cell...
6.
Ayerra L, Abellanas M, Basurco L, Tamayo I, Conde E, Tavira A, et al.
J Neuroinflammation
. 2024 Apr;
21(1):92.
PMID: 38610019
Glial cells are key players in the initiation of innate immunity in neurodegeneration. Upon damage, they switch their basal activation state and acquire new functions in a context and time-dependent...
7.
Aparicio B, Theunissen P, Hervas-Stubbs S, Fortes P, Sarobe P
Hum Vaccin Immunother
. 2024 Feb;
20(1):2303799.
PMID: 38346926
Efficacy of cancer immunotherapies relies on correct recognition of tumor antigens by lymphocytes, eliciting thus functional responses capable of eliminating tumor cells. Therefore, important efforts have been carried out in...
8.
Melero I, Ochoa M, Molina C, Sanchez-Gregorio S, Garasa S, Luri-Rey C, et al.
EMBO Mol Med
. 2023 Oct;
15(11):e17804.
PMID: 37782273
NK-cell reactivity against cancer is conceivably suppressed in the tumor microenvironment by the interaction of the inhibitory receptor NKG2A with the non-classical MHC-I molecules HLA-E in humans or Qa-1 in...
9.
Tomas-Velazquez A, Lopez-Gutierrez J, Reyes-Mugica M, Salgado C, Hervas-Stubbs S, de Andrea C, et al.
J Am Acad Dermatol
. 2023 Jul;
89(5):1074-1077.
PMID: 37495174
No abstract available.
10.
Olivera I, Bolanos E, Gonzalez-Gomariz J, Hervas-Stubbs S, Marino K, Luri-Rey C, et al.
Cell Rep Med
. 2023 Mar;
:100978.
PMID: 36933554
Interleukin-12 (IL-12) gene transfer enhances the therapeutic potency of adoptive T cell therapies. We previously reported that transient engineering of tumor-specific CD8 T cells with IL-12 mRNA enhanced their systemic...